USP India

USP India

Pharmaceutical Manufacturing

Hyderabad, Telangana 8,968 followers

Collaborating with regional partners to advance global health.

About us

USP India drives U.S. Pharmacopeia’s global efforts on advocacy of public health, capability-building and setting quality standards for medicines, dietary supplements, and food ingredients in the region. https://www.usp.org

Website
https://www.usp.org/usp-india
Industry
Pharmaceutical Manufacturing
Company size
201-500 employees
Headquarters
Hyderabad, Telangana
Founded
2005
Specialties
Medicines Quality

Updates

  • At US Pharmacopeia, we believe that true progress thrives on inclusivity. As we recently celebrated the International Day for People with Disabilities, we reaffirm our dedication to creating an environment where everyone—regardless of ability—can lead, grow, and thrive. Inclusivity isn’t just a value at USP; it’s embedded in our policies and culture. Through initiatives like our "Diverse Minds & Bodies Affinity Group", we provide a platform for individuals with disabilities to connect, advocate, and lead. This group plays a pivotal role in fostering a culture of support, mentorship, and collaboration, ensuring that every voice is heard and every perspective is valued. We’re proud of the progress we’ve made and remain dedicated to advancing our efforts. By amplifying the leadership and contributions of persons with disabilities, we move closer to a future that is truly inclusive, sustainable, and enriched by diverse talents. Join us in shaping this future! Explore opportunities with us here: https://usp.jobs/

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
  • The US Pharmacopeia leadership team recently visited the Indian Pharmacopoeia Commission to further strengthen our collaboration and drive meaningful outcomes in key areas such as supply chain resiliency, medicine quality, and capability building. Discussion explored opportunities for industry partnerships, joint events, and collaborative initiatives aimed at advancing shared goals. During the visit, Ronald Piervincenzi, CEO, USP, addressed IPC scientists, sharing his expertise and offering valuable insights on advancing global medicine quality standards. Additionally, Dr. Rajeev Raghuvanshi, DCGI, shared his perspectives on the PLI scheme, the importance of excipient quality, and strategies for enhancing India’s pharmaceutical landscape. This engagement highlights our shared commitment to ensuring medicine quality, building resilient supply chains, and fostering impactful collaborations that benefit public health globally. Stay tuned for more updates as we continue to work together towards our shared mission!

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
  • View organization page for USP India, graphic

    8,968 followers

    Recently, the leadership teams of US Pharmacopeia and Biotechnology Industry Research Assistance Council (BIRAC) came together to further our shared vision for advancing India's biomanufacturing sector. This pivotal meeting included Ronald Piervincenzi, CEO, USP, Jaap V. , CSO, USP along with Dr. Jitender Kumar, MD, BIRAC, and Dr. Sonia Gandhi, Deputy General Manager & Head, Regulatory Affairs & Policy Advocacy, BIRAC. USP and BIRAC officially completed the signing of the Letter of Intent, a significant milestone first announced at Global Bio India 2024. This collaboration underscores a shared vision to build capabilities in biomanufacturing, enhancing the quality of biopharmaceuticals and drive innovation in India's biomanufacturing ecosystem. We are excited to continue this partnership and work together to create impactful solutions that foster sustainable growth in the biopharmaceutical landscape.

    • No alternative text description for this image
  • USP India reposted this

    The FDA recently announced a Class II recall for more than 7,000 bottles of the antidepressant duloxetine (brand name: Cymbalta) due to the presence of nitrosamines a type of impurity in pharmaceuticals that can potentially increase cancer risk with long-term exposure. The last month saw additional recalls of medications also due to traces of nitrosamine-related impurities according to reports. Nitrosamine drug substance-related impurities (NDSRIs) are a class of impurities that can be formed in a variety of ways during a drug’s development and manufacture – from raw ingredients to manufacturing, packaging, and storage. The pharmaceutical industry and regulators are working to limit the presence of nitrosamines to ensure a safe medicine supply. Regulatory agencies around the world, including the U.S. FDA, work with manufacturers to establish safe levels of nitrosamines in medicines to prevent the need for recalls, which take place when unacceptable levels of the impurities are discovered in products. If you or someone you know is taking duloxetine, consult your healthcare provider for guidance. Read the infographic below ⤵️ to learn more about nitrosamines, what other medications have been recalled due to the impurities, and what USP is doing to help as industry prepares for an Aug 1, 2025 deadline to finalize confirmatory testing for NDSRIs in drug products and submit required changes to drug applications. 👉 Share this post to help others stay informed. #USPScience #FDARecall #duloxetine #nitrosamines

  • The Women in Pharma Roundtable at CPHI & PMEC India 2024 was a powerful platform for celebrating the impact of women leaders in the pharmaceutical and biopharmaceutical industries. Among the distinguished voices at the table was Dr. Mrunal Jaywant, VP R&D , USP India. who shared profound insights on key themes shaping the advancement of women in pharma. Generational challenges and biases that women face in leadership roles, emerging trends like digital health and precision medicine and how these advancements create unique opportunities for women leaders to shape the future of healthcare, from unconscious biases to structural challenges, Mrunal shared real-world strategies for navigating these obstacles while encouraging women to share their successes and learn from failures to build collective strength. 💡 At US Pharmacopeia, we believe in fostering a culture of diversity, equity, inclusion and belonging to empower talent and drive innovation in the pharma industry. Our commitment to building an inclusive workforce reflects in everything we do, from setting quality standards to supporting gender equality in leadership. If you’re inspired to make a difference and shape the future of healthcare, explore career opportunities at USP by visiting our careers page: https://usp.jobs/

    • No alternative text description for this image
    • No alternative text description for this image
  • In the dynamic world of pharmaceuticals, maintaining quality and regulatory compliance is not just a goal but a commitment to excellence. Matruprasad P.. Senior Director & General Manager – Regions & Program Operations USP, South Asia have been part of the transformative discussion on quality and compliance. sharing key insights on the role of robust quality systems, innovation, and collaboration in ensuring compliance in the face of evolving global regulations. Key themes from the session included: ✔️ Proactive Quality by Design approaches to mitigate risks. ✔️ Building resilient Quality Management Systems to ensure seamless compliance. ✔️ Cultivating a culture of compliance to uphold industry standards. ✔️ Embracing digital transformation for smarter and more efficient quality assurance. Moderated by Subhrangshu Chaudhury, VP & Head of Quality at Centaur Pharmaceuticals, the panel included esteemed leaders from Sandoz India Pvt Ltd, Takeda India, and Cipla, making this a truly impactful conversation. At USP, we are committed to supporting the pharma industry in its mission to deliver safe, effective, and high-quality medicines. To learn how US Pharmacopeia’s solutions help the industry navigate this evolving regulatory landscape, visit https://www.usp.org/. Let’s continue working together to raise the bar for quality and compliance! 💊✨

    • No alternative text description for this image
    • No alternative text description for this image
  • We had an exceptional time at CPHI & PMEC India 2024, connecting with pharma industry leaders, engaging in meaningful discussions, and reaffirming our commitment to advancing the quality of medicines. It was inspiring to witness pharma professionals actively engaging with our staff— exploring US Pharmacopeia's comprehensive solutions, and discussing collaborative ways to elevate quality standards in the pharmaceutical industry. A special shoutout to our authorized distributors Chromachemie Laboratory Private Limited and Ultra Group for their invaluable partnership and unwavering support. Together, we are making strides toward ensuring a resilient and high-quality pharmaceutical supply chain. For all the pharma professionals we met—or those who couldn’t connect with us during the event—our USP Account Managers are here to assist you with any queries. Additionally, stay connected with our authorized distributors to access USP solutions and support. Check: https://lnkd.in/gE5cCfv4 Let’s keep the conversations going as we work together to ensure the delivery of quality medicines across the globe. #CPhI2024 #USPIndia #AdvancingQuality #PharmaIndustry #MedicineQuality

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
  • "Join us at CPhI India! We're excited to announce that US Pharmacopeia will be participating in two panel sessions at CPHI & PMEC India : 1. Fireside Chat: Quality & Regulatory Compliance - Staying Compliant Always Date: November 26th, 3:35 PM - 4:15 PM Speaker: Matruprasad P. 2. Bridging Generations, Breaking Barriers, and Shaping the Future: Empowering Women in Pharma Date: November 27th, 11:30 AM - 1:30 PM Speaker: Mrunal Jaywant Visit us at our exhibition stalls: Registration Hall C32 Hall Number 7: P06 Meet our senior leadership, SCD teams and our Authorised Distributors to learn about the latest updates from US Pharmacopeia! Let's connect and shape the future of pharma together! #USPIndia #CPhIIndia #Pharma #QualityMatters"

    View organization page for CPhI Conferences, graphic

    11,127 followers

    Excited to introduce another stellar lineup of speakers for the Women in Pharma Conference! We’re thrilled to welcome Monisha Sharma, Ph.D., Sr. Clinical Research Director at MSD Pharmaceuticals; Dr. Mrunal Jaywant, VP of R&D at U US Pharmacopeia; and Mona Hakeem, VP of HR at Sun Pharmaceuticals Industries Ltd. For more details about the event please connect - Nirmal Shaha | nirmal.shaha@informa.com These inspiring leaders will share their expertise and insights, championing innovation and empowerment within the pharma industry. Don’t miss this impactful session! #WomenInPharma #CPHIIndia #PMECIndia #Leadership #Empowerment #PharmaInnovation #IndustryConnect #PharmaInnovations #CPHIAndPMECIndia2024 #PharmaLeadership #AtTheHeartOfPharma #CPHIIndia #PMECIndia Rahul Deshpande Ruchi Kedia Ketki Karkhanis Sheron David Mahesh Verma Dheeresh Bangera Nirmal Shaha Shreya Gupta

  • USP India reposted this

    At the 𝗖𝗣𝗛𝗜 & 𝗣𝗠𝗘𝗖 𝗜𝗻𝗱𝗶𝗮 𝗪𝗼𝗺𝗲𝗻 𝗶𝗻 𝗣𝗵𝗮𝗿𝗺𝗮 𝗥𝗼𝘂𝗻𝗱𝘁𝗮𝗯𝗹𝗲, we celebrate the resilience, innovation, and leadership of women who are shaping the future of pharma. This exclusive gathering highlights their journeys, tackles industry challenges, and explores opportunities for growth and empowerment within pharma and biotech. Together, we’re forging a path toward a more inclusive and dynamic industry. Now, as we look ahead, we can’t wait to see you at CPHI & PMEC India 2024 to continue these impactful conversations and foster even greater connections within the heart of pharma.  📅 26–28 November 2024  📍 India Expo Center, Greater Noida, Delhi NCR Moderator: Gaurav Sharma -India Procurement Lead Panelists: Dr. Madhavi Marathe, Dr. Ujwala Salvi, Mrunal Jaywant, Poonam Vats Dubey, Monisha Sharma, Ph.D., Jyotsna Ghoshal, Jyothi Sharma, Dr. Rupali Paranjape PhD, Prashant Katiyar, Rubina Parmar sodhi, Garima Mishra, Anjali Ramakrishna, PhD Join us in celebrating excellence and building the future. Register Now for CPHI & PMEC India 2024: https://lnkd.in/gTMdhnz2 #AtTheHeartOfPharma #CPHIAndPMECIndia2024 #WomenInPharma #Empowerment #PharmaLeadership #Innovation #PharmaExcellence Rahul Deshpande, Jayesh Kanaskar, Ketki Karkhanis, Shruti Save, Dheeresh Bangera, Sameer Matkar, Mahesh Verma, Devendra Bhosale, Kanishka Ahuja, Rohan Salian

  • We are excited to be part of CPHI & PMEC India 2024 in New Delhi, where we’ll connect with pharma industry professionals and share insights on critical topics shaping the future of the industry. One of the most important discussions will feature Matruprasad P., who will bring US Pharmacopeia’s perspective on quality and compliance in pharmaceutical industry. These conversations are vital as we work together to strengthen trust in medicines and advance global health. We look forward to engaging with you at this premier event. Let’s collaborate to address challenges and drive innovation !

    View organization page for CPHI & PMEC India, graphic

    7,923 followers

    𝗝𝗼𝗶𝗻 𝘂𝘀 𝗮𝘁 𝘁𝗵𝗲 𝗣𝗵𝗮𝗿𝗺𝗮 𝗖𝗼𝗻𝗻𝗲𝗰𝘁 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗱𝘂𝗿𝗶𝗻𝗴 𝗖𝗣𝗛𝗜 & 𝗣𝗠𝗘𝗖 𝗜𝗻𝗱𝗶𝗮 2024 for an insightful session on maintaining excellence in quality and regulatory compliance in the pharmaceutical industry! From 26-28 November 2024 at India Expo Centre (IEML), Greater Noida, Delhi NCR, this interactive fireside chat will be moderated by Subhrangshu Chaudhury, VP & Head of Quality at Centaur Pharmaceuticals Pvt. Ltd., and feature esteemed industry leaders: Meenakshi Jain – Head of Regulatory Generics Development, Sandoz India Matruprasad P. – Senior Director, Program Operations & GM - South Asia, USP-India Swati Kapoor – Head of Quality, Takeda India Vipul Kumar Gupta – VP & Head of Corporate Affairs & Policy, Cipla Don't miss this opportunity to gain valuable insights into driving compliance excellence! Register Now for CPHI & PMEC India 2024: https://bit.ly/3XNXzof For more information, please contact: Nirmal Shaha | +91 986 731 084 | nirmal.shaha@informa.com Be there to shape the future of quality and compliance in pharma! #AtTheHeartOfPharma #CPHIAndPMECIndia2024 #PharmaInnovation #PharmaConnection #PharmaConnect #PharmaConnectCongress Rahul Deshpande, Jayesh Kanaskar, Ketki Karkhanis, Shruti Save, Dheeresh Bangera, Sameer Matkar, Mahesh Verma, Devendra Bhosale, Kanishka Ahuja, Rohan Salian

    • No alternative text description for this image

Affiliated pages

Similar pages